Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing

Clin Pharmacol Ther. 2014 Dec;96(6):652-4. doi: 10.1038/clpt.2014.186.

Authors

A C J W Janssens¹, P A Deverka²

Affiliations

¹ 1] Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta Georgia, USA [2] Department of Clinical Genetics, VU Medical Center, Amsterdam, The Netherlands.
² Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Center for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina, USA.

PMID: 25399713
DOI: 10.1038/clpt.2014.186

No abstract available

MeSH terms

Cost-Benefit Analysis
Genetic Testing* / economics
Humans
Pharmacogenetics* / economics